![Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842823003219-gr1.jpg)
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect
![Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420325904-gr3.jpg)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
![Full article: Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials Full article: Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials](https://www.tandfonline.com/cms/asset/560a21d1-5648-431c-80a8-f4240fbb5d91/ieid_a_1964470_f0003_oc.jpg)
Full article: Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials
![Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842823003219-ga1.jpg)
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect
![Current and novel therapeutic opportunities for systemic therapy in biliary cancer | British Journal of Cancer Current and novel therapeutic opportunities for systemic therapy in biliary cancer | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0987-3/MediaObjects/41416_2020_987_Fig1_HTML.png)
Current and novel therapeutic opportunities for systemic therapy in biliary cancer | British Journal of Cancer
![Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2019/edbk.2019.39/edbk_237449/20190429/images/large/edbk_237449_table1.jpeg)
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
![Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives](https://www.frontiersin.org/files/Articles/860453/fonc-12-860453-HTML/image_m/fonc-12-860453-g001.jpg)
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
![Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - The Lancet Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/cca2159a-06c6-40ba-9763-7718ae915111/gr1.jpg)
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - The Lancet
![Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/261fc5ad-67f2-4186-933b-2707a2d4d1f0/gr3_lrg.jpg)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
![Abbreviations: GEMCIS, Gemcitabine and cisplatin combination therapy;... | Download Scientific Diagram Abbreviations: GEMCIS, Gemcitabine and cisplatin combination therapy;... | Download Scientific Diagram](https://www.researchgate.net/publication/355527821/figure/fig1/AS:1083465529335808@1635329720033/Abbreviations-GEMCIS-Gemcitabine-and-cisplatin-combination-therapy-ICR-independent.png)
Abbreviations: GEMCIS, Gemcitabine and cisplatin combination therapy;... | Download Scientific Diagram
![PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment](https://i1.rgstatic.net/publication/345369414_560P_Safety_and_efficacy_of_Debio_1143_an_antagonist_of_inhibitor_of_apoptosis_proteins_IAPs_in_combination_with_nivolumab_in_a_phase_IbII_trial_in_patients_pts_failing_prior_PD-1PD-L1_treatment/links/601bf98a45851589397e0bdc/largepreview.png)
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
![Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/9d936886-ca15-4872-902a-26350d1006bc/gr2_lrg.jpg)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
![Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach | Future Oncology Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2023-0098/asset/images/medium/figure2.gif)
Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach | Future Oncology
![Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420325904-gr5.jpg)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
![Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420325904-gr4.jpg)